The development of potent, competitive CXCR4 antagonists for the prevention of cancer metastasis
[Display omitted] Cancer metastasis is the cause of up to 90 % of cancer related mortality. The CXCR4 receptor and its cognate ligand, CXCL12, have major roles in enabling cancer metastasis and consequently, the CXCR4 receptor has become an attractive therapeutic target for the prevention of metasta...
Saved in:
| Published in | Biochemical pharmacology Vol. 218; p. 115921 |
|---|---|
| Main Authors | , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
Elsevier Inc
01.12.2023
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | [Display omitted]
Cancer metastasis is the cause of up to 90 % of cancer related mortality. The CXCR4 receptor and its cognate ligand, CXCL12, have major roles in enabling cancer metastasis and consequently, the CXCR4 receptor has become an attractive therapeutic target for the prevention of metastasis. Despite this, CXCR4 antagonists have had limited success in clinical trials due to cellular toxicity and poor stability and efficacy. In this study, we developed a novel, competitive CXCR4 antagonist (IS4) that through copper-catalysed-azide-alkyne-cycloaddition can be clicked to other chemical moieties such as fluorescent dyes (IS4-FAM) for CXCR4-based imaging. We determined that these CXCR4 antagonists were non-toxic and could be used to specifically label the CXCR4 receptor. Furthermore, IS4 and IS4-FAM inhibited CXCL12-stimulated cancer cell migration and Ca2+ release in both adherent and suspension cell lines with similar or improved potency as compared to two literature CXCR4 antagonists. Our results highlight the potential of IS4 and IS4-FAM as research tools and as potent CXCR4 antagonists for the prevention of metastasis. |
|---|---|
| AbstractList | Cancer metastasis is the cause of up to 90 % of cancer related mortality. The CXCR4 receptor and its cognate ligand, CXCL12, have major roles in enabling cancer metastasis and consequently, the CXCR4 receptor has become an attractive therapeutic target for the prevention of metastasis. Despite this, CXCR4 antagonists have had limited success in clinical trials due to cellular toxicity and poor stability and efficacy. In this study, we developed a novel, competitive CXCR4 antagonist (IS4) that through copper-catalysed-azide-alkyne-cycloaddition can be clicked to other chemical moieties such as fluorescent dyes (IS4-FAM) for CXCR4-based imaging. We determined that these CXCR4 antagonists were non-toxic and could be used to specifically label the CXCR4 receptor. Furthermore, IS4 and IS4-FAM inhibited CXCL12-stimulated cancer cell migration and Ca
release in both adherent and suspension cell lines with similar or improved potency as compared to two literature CXCR4 antagonists. Our results highlight the potential of IS4 and IS4-FAM as research tools and as potent CXCR4 antagonists for the prevention of metastasis. Cancer metastasis is the cause of up to 90 % of cancer related mortality. The CXCR4 receptor and its cognate ligand, CXCL12, have major roles in enabling cancer metastasis and consequently, the CXCR4 receptor has become an attractive therapeutic target for the prevention of metastasis. Despite this, CXCR4 antagonists have had limited success in clinical trials due to cellular toxicity and poor stability and efficacy. In this study, we developed a novel, competitive CXCR4 antagonist (IS4) that through copper-catalysed-azide-alkyne-cycloaddition can be clicked to other chemical moieties such as fluorescent dyes (IS4-FAM) for CXCR4-based imaging. We determined that these CXCR4 antagonists were non-toxic and could be used to specifically label the CXCR4 receptor. Furthermore, IS4 and IS4-FAM inhibited CXCL12-stimulated cancer cell migration and Ca2+ release in both adherent and suspension cell lines with similar or improved potency as compared to two literature CXCR4 antagonists. Our results highlight the potential of IS4 and IS4-FAM as research tools and as potent CXCR4 antagonists for the prevention of metastasis.Cancer metastasis is the cause of up to 90 % of cancer related mortality. The CXCR4 receptor and its cognate ligand, CXCL12, have major roles in enabling cancer metastasis and consequently, the CXCR4 receptor has become an attractive therapeutic target for the prevention of metastasis. Despite this, CXCR4 antagonists have had limited success in clinical trials due to cellular toxicity and poor stability and efficacy. In this study, we developed a novel, competitive CXCR4 antagonist (IS4) that through copper-catalysed-azide-alkyne-cycloaddition can be clicked to other chemical moieties such as fluorescent dyes (IS4-FAM) for CXCR4-based imaging. We determined that these CXCR4 antagonists were non-toxic and could be used to specifically label the CXCR4 receptor. Furthermore, IS4 and IS4-FAM inhibited CXCL12-stimulated cancer cell migration and Ca2+ release in both adherent and suspension cell lines with similar or improved potency as compared to two literature CXCR4 antagonists. Our results highlight the potential of IS4 and IS4-FAM as research tools and as potent CXCR4 antagonists for the prevention of metastasis. [Display omitted] Cancer metastasis is the cause of up to 90 % of cancer related mortality. The CXCR4 receptor and its cognate ligand, CXCL12, have major roles in enabling cancer metastasis and consequently, the CXCR4 receptor has become an attractive therapeutic target for the prevention of metastasis. Despite this, CXCR4 antagonists have had limited success in clinical trials due to cellular toxicity and poor stability and efficacy. In this study, we developed a novel, competitive CXCR4 antagonist (IS4) that through copper-catalysed-azide-alkyne-cycloaddition can be clicked to other chemical moieties such as fluorescent dyes (IS4-FAM) for CXCR4-based imaging. We determined that these CXCR4 antagonists were non-toxic and could be used to specifically label the CXCR4 receptor. Furthermore, IS4 and IS4-FAM inhibited CXCL12-stimulated cancer cell migration and Ca2+ release in both adherent and suspension cell lines with similar or improved potency as compared to two literature CXCR4 antagonists. Our results highlight the potential of IS4 and IS4-FAM as research tools and as potent CXCR4 antagonists for the prevention of metastasis. |
| ArticleNumber | 115921 |
| Author | Mueller, Anja Hamshaw, Isabel Cominetti, Marco M.D. Lai, Wing-Yee Searcey, Mark |
| Author_xml | – sequence: 1 givenname: Isabel surname: Hamshaw fullname: Hamshaw, Isabel – sequence: 2 givenname: Marco M.D. surname: Cominetti fullname: Cominetti, Marco M.D. – sequence: 3 givenname: Wing-Yee surname: Lai fullname: Lai, Wing-Yee – sequence: 4 givenname: Mark surname: Searcey fullname: Searcey, Mark – sequence: 5 givenname: Anja orcidid: 0000-0003-0774-0434 surname: Mueller fullname: Mueller, Anja email: anja.mueller@uea.ac.uk |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/37956893$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kMGKFDEQQIOsuLOrH-BFcvTgjKlkOt3Bkwy6KywIsoK3mEkqmqE7aZPMgH9vmlk9eFgoSAXeq8O7IhcxRSTkJbANMJBvD5u9nTeccbEB6BSHJ2QFQy_WXMnhgqwYY7LtHb8kV6Uclu8g4Rm5FL3q5KDEiny__4nU4QnHNE8YK02ezqm27Q21aZqxhhpOSHffdl-21MRqfqQYSi3Up0xrk-fc7FhDiotrTbSY6YTVlDahPCdPvRkLvnh4r8nXjx_ud7fru883n3bv79ZWKFnXQjLfb3spGHLppHNM4XY_eGsABi-9UM5uvUIJloFSwjgrWddZrqBzQ-fENXl9vjvn9OuIpeopFIvjaCKmY9F8UNB3ogfe0FcP6HE_odNzDpPJv_XfKg2AM2BzKiWj_4cA00t5fdCtvF7K63P55vT_OTZUs2Sp2YTxUfPd2cSW5xQw62IDtowuZLRVuxQesf8AQeydFg |
| CitedBy_id | crossref_primary_10_1097_MNM_0000000000001806 crossref_primary_10_3892_ol_2025_14899 crossref_primary_10_1002_prp2_70003 crossref_primary_10_3390_ijms25074102 crossref_primary_10_1080_15321819_2025_2482642 crossref_primary_10_3390_biology13110860 |
| Cites_doi | 10.1073/pnas.0503039102 10.1039/C7SC01342F 10.1038/35065016 10.1016/j.archoralbio.2017.07.012 10.3322/caac.21660 10.1021/ol047955x 10.1128/JVI.75.19.8957-8967.2001 10.1021/ja210335f 10.3389/fphar.2022.836710 10.1517/13543780903535867 10.1073/pnas.89.12.5286 10.3389/fimmu.2015.00012 10.1006/exmp.1999.2299 10.1016/S0092-8674(00)81393-8 10.1002/cam4.2474 10.1038/sj.onc.1210120 10.1002/cbic.201100441 10.1038/labinvest.3700181 10.1128/jvi.71.6.4744-4751.1997 10.18632/oncotarget.1426 10.1371/journal.pone.0074548 10.1128/AAC.38.4.668 10.1016/j.bcp.2006.05.010 10.1016/j.dci.2003.09.006 10.3389/fimmu.2015.00429 10.1182/blood-2008-09-177287 10.2144/000113463 10.1021/acs.jmedchem.6b00695 10.1182/blood-2008-08-174946 10.1007/s11095-008-9616-1 10.3390/pharmaceutics14081541 10.1128/JVI.73.8.6598-6609.1999 10.1016/j.coph.2008.06.002 10.1021/bc100272z 10.3322/caac.21763 10.1074/jbc.M106582200 10.1042/bst0320366 10.1074/jbc.M309546200 10.1371/journal.pone.0178943 10.1158/1078-0432.CCR-09-2329 10.1038/nature01874 10.1002/1521-3773(20010601)40:11<2004::AID-ANIE2004>3.0.CO;2-5 10.1371/journal.pone.0098231 10.1016/j.tips.2004.06.006 10.1126/scisignal.aay5024 10.1128/JVI.79.3.1930-1933.2005 10.1124/mol.60.1.164 10.1042/BST20201114 10.1517/14622416.5.6.657 |
| ContentType | Journal Article |
| Copyright | 2023 The Author(s) Copyright © 2023 The Author(s). Published by Elsevier Inc. All rights reserved. |
| Copyright_xml | – notice: 2023 The Author(s) – notice: Copyright © 2023 The Author(s). Published by Elsevier Inc. All rights reserved. |
| DBID | 6I. AAFTH AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1016/j.bcp.2023.115921 |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Chemistry Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1873-2968 |
| ExternalDocumentID | 37956893 10_1016_j_bcp_2023_115921 S0006295223005142 |
| Genre | Journal Article |
| GroupedDBID | --- --K --M -~X .55 .GJ .HR .~1 0R~ 1B1 1RT 1~. 1~5 23N 3O- 4.4 457 4G. 53G 5GY 5RE 5VS 6I. 6J9 7-5 71M 8P~ 9JM AABNK AACTN AAEDT AAEDW AAFTH AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AAXKI AAXUO AAYJJ ABFNM ABFRF ABJNI ABLJU ABMAC ABXDB ABZDS ACDAQ ACGFO ACGFS ACIUM ACNCT ACRLP ADBBV ADEZE ADMUD AEBSH AEFWE AEKER AENEX AFFNX AFJKZ AFKWA AFTJW AFXIZ AGHFR AGUBO AGYEJ AHHHB AI. AIEXJ AIKHN AITUG AJOXV AKRWK ALCLG ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC C45 CS3 DU5 EBS EFJIC EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HMT HVGLF HZ~ IH2 IHE J1W K-O KOM L7B LPU M34 M41 MO0 N9A O-L O9- OAUVE OGGZJ OVD OZT P-8 P-9 P2P PC. Q38 R2- RIG ROL RPZ SDF SDG SDP SES SEW SPCBC SPT SSP SSZ T5K TEORI TWZ VH1 WH7 WUQ X7M ZGI ZXP ~G- AATTM AAYWO AAYXX ABWVN ACRPL ACVFH ADCNI ADNMO AEIPS AEUPX AFPUW AGCQF AGQPQ AGRNS AIGII AIIUN AKBMS AKYEP ANKPU APXCP BNPGV CITATION SSH CGR CUY CVF ECM EIF NPM PKN 7X8 EFKBS |
| ID | FETCH-LOGICAL-c396t-360f747630e26d6dd09e4b8fca118f6f39dc4f9e61c01993adc6055c2915d85d3 |
| IEDL.DBID | .~1 |
| ISSN | 0006-2952 1873-2968 |
| IngestDate | Mon Jul 21 09:48:51 EDT 2025 Wed Feb 19 02:04:58 EST 2025 Tue Jul 01 02:23:47 EDT 2025 Thu Apr 24 23:03:49 EDT 2025 Sat Nov 09 16:01:03 EST 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | MALDI-TOF Maleimide Migration DIPEA CXCR4 pIC50 Chemokine receptor TFA DCM ECL NMP CXCR4 antagonist CXCL12 FAM EDT CuAAC IC50 HBTU HoBt DMF TIPS |
| Language | English |
| License | This is an open access article under the CC BY-NC license. Copyright © 2023 The Author(s). Published by Elsevier Inc. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c396t-360f747630e26d6dd09e4b8fca118f6f39dc4f9e61c01993adc6055c2915d85d3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ORCID | 0000-0003-0774-0434 |
| OpenAccessLink | https://www.sciencedirect.com/science/article/pii/S0006295223005142 |
| PMID | 37956893 |
| PQID | 2891753712 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_2891753712 pubmed_primary_37956893 crossref_primary_10_1016_j_bcp_2023_115921 crossref_citationtrail_10_1016_j_bcp_2023_115921 elsevier_sciencedirect_doi_10_1016_j_bcp_2023_115921 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | December 2023 2023-12-00 20231201 |
| PublicationDateYYYYMMDD | 2023-12-01 |
| PublicationDate_xml | – month: 12 year: 2023 text: December 2023 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England |
| PublicationTitle | Biochemical pharmacology |
| PublicationTitleAlternate | Biochem Pharmacol |
| PublicationYear | 2023 |
| Publisher | Elsevier Inc |
| Publisher_xml | – name: Elsevier Inc |
| References | Ahmed, Johnson, Solanki, Afewerki, Wostear, Warren (b0150) 2022; 13 Sarvaiya, Guo, Ulasov, Gabikian, Lesniak (b0025) 2013; 4 Pawig, Klasen, Weber, Bernhagen, Noels (b0175) 2015; 6 Kolb, Finn, Sharpless (b0260) 2001; 40 Staller, Sulitkova, Lisztwan, Moch, Oakeley, Krek (b0080) 2003; 425 Chen, Wang, Meng, Zhang, Wang, Jiang, Yu, Cui, Li (b0170) 2014; 9 DiPersio, Stadtmauer, Nademanee, Micallef, Stiff, Kaufman, Maziarz, Hosing, Früehauf, Horwitz (b0100) 2009; 113 Z. Johnson, C. Power, C. Weiss, F. Rintelen, H. Ji, T. Ruckle, M. Camps, T. Wells, M. Schwarz, A. Proudfoot, Chemokine inhibition–why, when, where, which and how?, Biochemical Society (2004). Stephens, Ngo, Kufareva, Handel (b0165) 2020; 13 Knight, Hallett, Brancale, Paisey, Clarkson, Edwards (b0215) 2011; 12 Müller, Homey, Soto, Ge, Catron, Buchanan, McClanahan, Murphy, Yuan, Wagner (b0065) 2001; 410 Li, Lee, Lu, Wang (b0140) 2010; 49 Chaffer, Weinberg (b0020) 2011; 331 Koshiba, Hosotani, Miyamoto, Ida, Tsuji, Nakajima, Kawaguchi, Kobayashi, Doi, Hori (b0055) 2000; 6 Eash, Means, White, Link (b0045) 2009; 113 E. De Clercq, N. Yamamoto, R. Pauwels, M. Baba, D. Schols, H. Nakashima, J. Balzarini, Z. Debyser, B.A. Murrer, D. Schwartz, Potent and selective inhibition of human immunodeficiency virus (HIV)-1 and HIV-2 replication by a class of bicyclams interacting with a viral uncoating event, Proceedings of the National Academy of Sciences 89(12) (1992) 5286-5290. Scotton, Wilson, Milliken, Stamp, Balkwill (b0070) 2001; 61 Hong, Steinmetz, Manchester, Finn (b0130) 2010; 21 Lefkowitz (b0240) 2004; 25 Endres, Clapham, Marsh, Ahuja, Turner, McKnight, Thomas, Stoebenau-Haggarty, Choe, Vance (b0220) 1996; 87 M.G. Borrello, L. Alberti, A. Fischer, D. Degl'Innocenti, C. Ferrario, M. Gariboldi, F. Marchesi, P. Allavena, A. Greco, P. Collini, Induction of a proinflammatory program in normal human thyrocytes by the RET/PTC1 oncogene, Proceedings of the National Academy of Sciences of the United States of America 102(41) (2005) 14825-14830. Mehta, Christopherson, Bhat-Nakshatri, Goulet, Broxmeyer, Kopelovich, Nakshatri (b0060) 2007; 26 Hein, Liu, Wang (b0135) 2008; 25 Xiao, Norwood, Feng, Moriuchi, Jones-Trower, Stantchev, Moriuchi, Broder, Dimitrov (b0160) 2000; 68 Portella, Vitale, De Luca, D’Alterio, Ierano, Napolitano, Riccio, Polimeno, Monfregola, Barbieri (b0115) 2013; 8 Phattarataratip, Dhanuthai (b0090) 2017; 83 De Clercq, Yamamoto, Pauwels, Balzarini, Witvrouw, De Vreese, Debyser, Rosenwirth, Peichl, Datema (b0195) 1994; 38 Sivakumar, Xie, Cash, Long, Barnhill, Wang (b0145) 2004; 6 Di Maro, Trotta, Brancaccio, Di Leva, La Pietra, Ierano, Napolitano, Portella, D’Alterio, Siciliano (b0120) 2016; 59 Baribaud, Edwards, Sharron, Brelot, Heveker, Price, Mortari, Alizon, Tsang, Doms (b0155) 2001; 75 Zhao, Liu, Li, Zhang, Wang, Zhang (b0105) 2022; 14 Grison, Burslem, Miles, Pilsl, Yeo, Imani, Warriner, Webb, Wilson (b0125) 2017; 8 Chabot, Zhang, Quinnan, Broder (b0230) 1999; 73 Singh, Singh, Grizzle, Lillard (b0075) 2004; 84 Böttger, Hoffmann, Knappe (b0245) 2017; 12 R.L. Siegel, K.D. Miller, N.S. Wagle, A. Jemal, Cancer statistics, 2023, CA: a cancer journal for clinicians 73(1) (2023) 17-48. Jones, Strickland, Schumacher, Caddick, Baker, Gibson, Haddleton (b0255) 2012; 134 Teicher, Fricker (b0035) 2010; 16 Brelot, Heveker, Pleskoff, Sol, Alizon (b0225) 1997; 71 Rosenkilde, Gerlach, Jakobsen, Skerlj, Bridger, Schwartz (b0205) 2004; 279 Mertens, Vandingenen, Meeusen, De Loof, Schoofs (b0235) 2004; 5 Fricker, Anastassov, Cox, Darkes, Grujic, Idzan, Labrecque, Lau, Mosi, Nelson (b0210) 2006; 72 Zhou, Luo, Luo, Liu, Hall, Pomerantz, Huang (b0180) 2001; 276 Hatse, Princen, Gerlach, Bridger, Henson, De Clercq, Schwartz, Schols (b0200) 2001; 60 Carnec, Quan, Olson, Hazan, Dragic (b0185) 2005; 79 Laing, Secombes (b0030) 2004; 28 Vela, Aris, Llorente, Garcia-Sanz, Kremer (b0085) 2015; 6 McGregor (b0250) 2008; 8 Sung, Ferlay, Siegel, Laversanne, Soerjomataram, Jemal, Bray (b0010) 2021; 71 Proudfoot, Power, Schwarz (b0110) 2010; 19 Dillekås, Rogers, Straume (b0015) 2019; 8 Lai, Mueller (b0040) 2021; 49 DiPersio (10.1016/j.bcp.2023.115921_b0100) 2009; 113 Jones (10.1016/j.bcp.2023.115921_b0255) 2012; 134 Portella (10.1016/j.bcp.2023.115921_b0115) 2013; 8 Hein (10.1016/j.bcp.2023.115921_b0135) 2008; 25 Staller (10.1016/j.bcp.2023.115921_b0080) 2003; 425 Grison (10.1016/j.bcp.2023.115921_b0125) 2017; 8 Böttger (10.1016/j.bcp.2023.115921_b0245) 2017; 12 Scotton (10.1016/j.bcp.2023.115921_b0070) 2001; 61 Koshiba (10.1016/j.bcp.2023.115921_b0055) 2000; 6 Teicher (10.1016/j.bcp.2023.115921_b0035) 2010; 16 Vela (10.1016/j.bcp.2023.115921_b0085) 2015; 6 Kolb (10.1016/j.bcp.2023.115921_b0260) 2001; 40 Eash (10.1016/j.bcp.2023.115921_b0045) 2009; 113 Ahmed (10.1016/j.bcp.2023.115921_b0150) 2022; 13 Chen (10.1016/j.bcp.2023.115921_b0170) 2014; 9 Müller (10.1016/j.bcp.2023.115921_b0065) 2001; 410 10.1016/j.bcp.2023.115921_b0095 10.1016/j.bcp.2023.115921_b0050 Chabot (10.1016/j.bcp.2023.115921_b0230) 1999; 73 Xiao (10.1016/j.bcp.2023.115921_b0160) 2000; 68 Lefkowitz (10.1016/j.bcp.2023.115921_b0240) 2004; 25 Pawig (10.1016/j.bcp.2023.115921_b0175) 2015; 6 Chaffer (10.1016/j.bcp.2023.115921_b0020) 2011; 331 Laing (10.1016/j.bcp.2023.115921_b0030) 2004; 28 Proudfoot (10.1016/j.bcp.2023.115921_b0110) 2010; 19 Zhou (10.1016/j.bcp.2023.115921_b0180) 2001; 276 Knight (10.1016/j.bcp.2023.115921_b0215) 2011; 12 10.1016/j.bcp.2023.115921_b0005 Mehta (10.1016/j.bcp.2023.115921_b0060) 2007; 26 Dillekås (10.1016/j.bcp.2023.115921_b0015) 2019; 8 Stephens (10.1016/j.bcp.2023.115921_b0165) 2020; 13 Mertens (10.1016/j.bcp.2023.115921_b0235) 2004; 5 Lai (10.1016/j.bcp.2023.115921_b0040) 2021; 49 Di Maro (10.1016/j.bcp.2023.115921_b0120) 2016; 59 Brelot (10.1016/j.bcp.2023.115921_b0225) 1997; 71 Fricker (10.1016/j.bcp.2023.115921_b0210) 2006; 72 Endres (10.1016/j.bcp.2023.115921_b0220) 1996; 87 Sung (10.1016/j.bcp.2023.115921_b0010) 2021; 71 Rosenkilde (10.1016/j.bcp.2023.115921_b0205) 2004; 279 Sarvaiya (10.1016/j.bcp.2023.115921_b0025) 2013; 4 Zhao (10.1016/j.bcp.2023.115921_b0105) 2022; 14 McGregor (10.1016/j.bcp.2023.115921_b0250) 2008; 8 De Clercq (10.1016/j.bcp.2023.115921_b0195) 1994; 38 Baribaud (10.1016/j.bcp.2023.115921_b0155) 2001; 75 10.1016/j.bcp.2023.115921_b0190 Carnec (10.1016/j.bcp.2023.115921_b0185) 2005; 79 Hatse (10.1016/j.bcp.2023.115921_b0200) 2001; 60 Li (10.1016/j.bcp.2023.115921_b0140) 2010; 49 Singh (10.1016/j.bcp.2023.115921_b0075) 2004; 84 Sivakumar (10.1016/j.bcp.2023.115921_b0145) 2004; 6 Phattarataratip (10.1016/j.bcp.2023.115921_b0090) 2017; 83 Hong (10.1016/j.bcp.2023.115921_b0130) 2010; 21 |
| References_xml | – volume: 410 start-page: 50 year: 2001 end-page: 56 ident: b0065 article-title: Involvement of chemokine receptors in breast cancer metastasis publication-title: Nature – volume: 8 start-page: e74548 year: 2013 ident: b0115 article-title: Preclinical development of a novel class of CXCR4 antagonist impairing solid tumors growth and metastases publication-title: PLoS One – reference: M.G. Borrello, L. Alberti, A. Fischer, D. Degl'Innocenti, C. Ferrario, M. Gariboldi, F. Marchesi, P. Allavena, A. Greco, P. Collini, Induction of a proinflammatory program in normal human thyrocytes by the RET/PTC1 oncogene, Proceedings of the National Academy of Sciences of the United States of America 102(41) (2005) 14825-14830. – volume: 13 start-page: 148 year: 2022 ident: b0150 article-title: Using polyacrylamide hydrogels to model physiological aortic stiffness reveals that microtubules are critical regulators of isolated smooth muscle cell morphology and contractility publication-title: Front. Pharmacol. – reference: R.L. Siegel, K.D. Miller, N.S. Wagle, A. Jemal, Cancer statistics, 2023, CA: a cancer journal for clinicians 73(1) (2023) 17-48. – volume: 8 start-page: 5574 year: 2019 end-page: 5576 ident: b0015 article-title: Are 90% of deaths from cancer caused by metastases? publication-title: Cancer Med. – volume: 28 start-page: 443 year: 2004 end-page: 460 ident: b0030 article-title: Chemokines publication-title: Dev. Comp. Immunol. – volume: 6 start-page: 3530 year: 2000 end-page: 3535 ident: b0055 article-title: Expression of stromal cell-derived factor 1 and CXCR4 ligand receptor system in pancreatic cancer: a possible role for tumor progression publication-title: Clin. Cancer Res. – volume: 75 start-page: 8957 year: 2001 end-page: 8967 ident: b0155 article-title: Antigenically distinct conformations of CXCR4 publication-title: J. Virol. – volume: 9 start-page: e98231 year: 2014 ident: b0170 article-title: CXC chemokine CXCL12 and its receptor CXCR4 in tree shrews (Tupaia belangeri): structure, expression and function publication-title: PLoS One – volume: 331 start-page: 1559 year: 2011 end-page: 1564 ident: b0020 publication-title: A Perspective on Cancer Cell Metastasis, Science – volume: 21 start-page: 1912 year: 2010 end-page: 1916 ident: b0130 article-title: Labeling live cells by copper-catalyzed alkyne− azide click chemistry publication-title: Bioconjug. Chem. – volume: 60 start-page: 164 year: 2001 end-page: 173 ident: b0200 article-title: Mutation of Asp171 and Asp262 of the chemokine receptor CXCR4 impairs its coreceptor function for human immunodeficiency virus-1 entry and abrogates the antagonistic activity of AMD3100 publication-title: Mol. Pharmacol. – volume: 113 start-page: 4711 year: 2009 end-page: 4719 ident: b0045 article-title: CXCR4 is a key regulator of neutrophil release from the bone marrow under basal and stress granulopoiesis conditions publication-title: Blood – volume: 83 start-page: 136 year: 2017 end-page: 144 ident: b0090 article-title: Expression of CXC motif chemokine receptors 4 and 7 in salivary gland neoplasms publication-title: Arch. Oral Biol. – reference: E. De Clercq, N. Yamamoto, R. Pauwels, M. Baba, D. Schols, H. Nakashima, J. Balzarini, Z. Debyser, B.A. Murrer, D. Schwartz, Potent and selective inhibition of human immunodeficiency virus (HIV)-1 and HIV-2 replication by a class of bicyclams interacting with a viral uncoating event, Proceedings of the National Academy of Sciences 89(12) (1992) 5286-5290. – volume: 40 start-page: 2004 year: 2001 end-page: 2021 ident: b0260 article-title: Click chemistry: diverse chemical function from a few good reactions publication-title: Angew. Chem. Int. Ed. – volume: 113 start-page: 5720 year: 2009 end-page: 5726 ident: b0100 article-title: Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma publication-title: Blood – volume: 79 start-page: 1930 year: 2005 end-page: 1933 ident: b0185 article-title: Anti-CXCR4 monoclonal antibodies recognizing overlapping epitopes differ significantly in their ability to inhibit entry of human immunodeficiency virus type 1 publication-title: J. Virol. – volume: 12 start-page: e0178943 year: 2017 ident: b0245 article-title: Differential stability of therapeutic peptides with different proteolytic cleavage sites in blood, plasma and serum publication-title: PLoS One – reference: Z. Johnson, C. Power, C. Weiss, F. Rintelen, H. Ji, T. Ruckle, M. Camps, T. Wells, M. Schwarz, A. Proudfoot, Chemokine inhibition–why, when, where, which and how?, Biochemical Society (2004). – volume: 84 start-page: 1666 year: 2004 end-page: 1676 ident: b0075 article-title: CXCL12–CXCR4 interactions modulate prostate cancer cell migration, metalloproteinase expression and invasion publication-title: Lab. Invest. – volume: 49 start-page: 525 year: 2010 end-page: 527 ident: b0140 article-title: Fluorogenic “click” reaction for labeling and detection of DNA in proliferating cells publication-title: Biotechniques – volume: 425 start-page: 307 year: 2003 end-page: 311 ident: b0080 article-title: Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL publication-title: Nature – volume: 14 start-page: 1541 year: 2022 ident: b0105 article-title: Recent Advances in CXCL12/CXCR4 Antagonists and Nano-Based Drug Delivery Systems for Cancer Therapy publication-title: Pharmaceutics – volume: 8 start-page: 616 year: 2008 end-page: 619 ident: b0250 article-title: Discovering and improving novel peptide therapeutics publication-title: Curr. Opin. Pharmacol. – volume: 25 start-page: 413 year: 2004 end-page: 422 ident: b0240 article-title: Historical review: a brief history and personal retrospective of seven-transmembrane receptors publication-title: Trends Pharmacol. Sci. – volume: 6 year: 2015 ident: b0175 article-title: Diversity and inter-connections in the CXCR4 chemokine receptor/ligand family: molecular perspectives publication-title: Front. Immunol. – volume: 6 start-page: 12 year: 2015 ident: b0085 article-title: Chemokine receptor-specific antibodies in cancer immunotherapy: achievements and challenges publication-title: Front. Immunol. – volume: 134 start-page: 1847 year: 2012 end-page: 1852 ident: b0255 article-title: Polymeric dibromomaleimides as extremely efficient disulfide bridging bioconjugation and pegylation agents publication-title: J. Am. Chem. Soc. – volume: 16 start-page: 2927 year: 2010 end-page: 2931 ident: b0035 article-title: CXCL12 (SDF-1)/CXCR4 pathway in cancer publication-title: Clin. Cancer Res. – volume: 71 start-page: 209 year: 2021 end-page: 249 ident: b0010 article-title: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries publication-title: CA Cancer J. Clin. – volume: 12 start-page: 2692 year: 2011 end-page: 2698 ident: b0215 article-title: Evaluation of a fluorescent derivative of AMD3100 and its interaction with the CXCR4 chemokine receptor publication-title: Chembiochem – volume: 13 start-page: eaay5024 year: 2020 ident: b0165 article-title: Functional anatomy of the full-length CXCR4-CXCL12 complex systematically dissected by quantitative model-guided mutagenesis publication-title: Sci. Signal. – volume: 87 start-page: 745 year: 1996 end-page: 756 ident: b0220 article-title: CD4-independent infection by HIV-2 is mediated by fusin/CXCR4 publication-title: Cell – volume: 73 start-page: 6598 year: 1999 end-page: 6609 ident: b0230 article-title: Mutagenesis of CXCR4 identifies important domains for human immunodeficiency virus type 1 X4 isolate envelope-mediated membrane fusion and virus entry and reveals cryptic coreceptor activity for R5 isolates publication-title: J. Virol. – volume: 4 start-page: 2171 year: 2013 ident: b0025 article-title: Chemokines in tumor progression and metastasis publication-title: Oncotarget – volume: 59 start-page: 8369 year: 2016 end-page: 8380 ident: b0120 article-title: Exploring the N-terminal region of CXC motif chemokine 12 (CXCL12): Identification of plasma-stable cyclic peptides as novel, potent CXC chemokine receptor type 4 (CXCR4) antagonists publication-title: J. Med. Chem. – volume: 19 start-page: 345 year: 2010 end-page: 355 ident: b0110 article-title: Anti-chemokine small molecule drugs: a promising future? publication-title: Expert Opin. Invest. Drugs – volume: 8 start-page: 5166 year: 2017 end-page: 5171 ident: b0125 article-title: Double quick, double click reversible peptide “stapling” publication-title: Chem. Sci. – volume: 26 start-page: 3329 year: 2007 end-page: 3337 ident: b0060 article-title: Negative regulation of chemokine receptor CXCR4 by tumor suppressor p53 in breast cancer cells: implications of p53 mutation or isoform expression on breast cancer cell invasion publication-title: Oncogene – volume: 68 start-page: 139 year: 2000 end-page: 146 ident: b0160 article-title: Inefficient Formation of a Complex among CXCR4, CD4 and gp120 in U937 Clones Resistant to X4 gp120–gp41-Mediated Fusion publication-title: Exp. Mol. Pathol. – volume: 49 start-page: 1385 year: 2021 end-page: 1395 ident: b0040 article-title: Latest update on chemokine receptors as therapeutic targets publication-title: Biochem. Soc. Trans. – volume: 61 start-page: 4961 year: 2001 end-page: 4965 ident: b0070 article-title: Epithelial cancer cell migration publication-title: Cancer Res. – volume: 5 start-page: 657 year: 2004 end-page: 672 ident: b0235 article-title: Postgenomic characterization of G-protein-coupled receptors publication-title: Pharmacogenomics – volume: 71 start-page: 4744 year: 1997 end-page: 4751 ident: b0225 article-title: Role of the first and third extracellular domains of CXCR-4 in human immunodeficiency virus coreceptor activity publication-title: J. Virol. – volume: 25 start-page: 2216 year: 2008 end-page: 2230 ident: b0135 article-title: Click chemistry, a powerful tool for pharmaceutical sciences publication-title: Pharm. Res. – volume: 6 start-page: 4603 year: 2004 end-page: 4606 ident: b0145 article-title: A fluorogenic 1, 3-dipolar cycloaddition reaction of 3-azidocoumarins and acetylenes publication-title: Org. Lett. – volume: 72 start-page: 588 year: 2006 end-page: 596 ident: b0210 article-title: Characterization of the molecular pharmacology of AMD3100: a specific antagonist of the G-protein coupled chemokine receptor, CXCR4 publication-title: Biochem. Pharmacol. – volume: 279 start-page: 3033 year: 2004 end-page: 3041 ident: b0205 article-title: Molecular mechanism of AMD3100 antagonism in the CXCR4 receptor: transfer of binding site to the CXCR3 receptor publication-title: J. Biol. Chem. – volume: 38 start-page: 668 year: 1994 end-page: 674 ident: b0195 article-title: Highly potent and selective inhibition of human immunodeficiency virus by the bicyclam derivative JM3100 publication-title: Antimicrob. Agents Chemother. – volume: 276 start-page: 42826 year: 2001 end-page: 42833 ident: b0180 article-title: Structural and functional characterization of human CXCR4 as a chemokine receptor and HIV-1 co-receptor by mutagenesis and molecular modeling studies publication-title: J. Biol. Chem. – ident: 10.1016/j.bcp.2023.115921_b0050 doi: 10.1073/pnas.0503039102 – volume: 8 start-page: 5166 issue: 7 year: 2017 ident: 10.1016/j.bcp.2023.115921_b0125 article-title: Double quick, double click reversible peptide “stapling” publication-title: Chem. Sci. doi: 10.1039/C7SC01342F – volume: 410 start-page: 50 issue: 6824 year: 2001 ident: 10.1016/j.bcp.2023.115921_b0065 article-title: Involvement of chemokine receptors in breast cancer metastasis publication-title: Nature doi: 10.1038/35065016 – volume: 83 start-page: 136 year: 2017 ident: 10.1016/j.bcp.2023.115921_b0090 article-title: Expression of CXC motif chemokine receptors 4 and 7 in salivary gland neoplasms publication-title: Arch. Oral Biol. doi: 10.1016/j.archoralbio.2017.07.012 – volume: 71 start-page: 209 issue: 3 year: 2021 ident: 10.1016/j.bcp.2023.115921_b0010 article-title: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries publication-title: CA Cancer J. Clin. doi: 10.3322/caac.21660 – volume: 6 start-page: 4603 issue: 24 year: 2004 ident: 10.1016/j.bcp.2023.115921_b0145 article-title: A fluorogenic 1, 3-dipolar cycloaddition reaction of 3-azidocoumarins and acetylenes publication-title: Org. Lett. doi: 10.1021/ol047955x – volume: 75 start-page: 8957 issue: 19 year: 2001 ident: 10.1016/j.bcp.2023.115921_b0155 article-title: Antigenically distinct conformations of CXCR4 publication-title: J. Virol. doi: 10.1128/JVI.75.19.8957-8967.2001 – volume: 134 start-page: 1847 issue: 3 year: 2012 ident: 10.1016/j.bcp.2023.115921_b0255 article-title: Polymeric dibromomaleimides as extremely efficient disulfide bridging bioconjugation and pegylation agents publication-title: J. Am. Chem. Soc. doi: 10.1021/ja210335f – volume: 13 start-page: 148 year: 2022 ident: 10.1016/j.bcp.2023.115921_b0150 article-title: Using polyacrylamide hydrogels to model physiological aortic stiffness reveals that microtubules are critical regulators of isolated smooth muscle cell morphology and contractility publication-title: Front. Pharmacol. doi: 10.3389/fphar.2022.836710 – volume: 61 start-page: 4961 issue: 13 year: 2001 ident: 10.1016/j.bcp.2023.115921_b0070 article-title: Epithelial cancer cell migration publication-title: Cancer Res. – volume: 19 start-page: 345 issue: 3 year: 2010 ident: 10.1016/j.bcp.2023.115921_b0110 article-title: Anti-chemokine small molecule drugs: a promising future? publication-title: Expert Opin. Invest. Drugs doi: 10.1517/13543780903535867 – volume: 6 start-page: 3530 issue: 9 year: 2000 ident: 10.1016/j.bcp.2023.115921_b0055 article-title: Expression of stromal cell-derived factor 1 and CXCR4 ligand receptor system in pancreatic cancer: a possible role for tumor progression publication-title: Clin. Cancer Res. – ident: 10.1016/j.bcp.2023.115921_b0190 doi: 10.1073/pnas.89.12.5286 – volume: 6 start-page: 12 year: 2015 ident: 10.1016/j.bcp.2023.115921_b0085 article-title: Chemokine receptor-specific antibodies in cancer immunotherapy: achievements and challenges publication-title: Front. Immunol. doi: 10.3389/fimmu.2015.00012 – volume: 68 start-page: 139 issue: 3 year: 2000 ident: 10.1016/j.bcp.2023.115921_b0160 article-title: Inefficient Formation of a Complex among CXCR4, CD4 and gp120 in U937 Clones Resistant to X4 gp120–gp41-Mediated Fusion publication-title: Exp. Mol. Pathol. doi: 10.1006/exmp.1999.2299 – volume: 87 start-page: 745 issue: 4 year: 1996 ident: 10.1016/j.bcp.2023.115921_b0220 article-title: CD4-independent infection by HIV-2 is mediated by fusin/CXCR4 publication-title: Cell doi: 10.1016/S0092-8674(00)81393-8 – volume: 8 start-page: 5574 issue: 12 year: 2019 ident: 10.1016/j.bcp.2023.115921_b0015 article-title: Are 90% of deaths from cancer caused by metastases? publication-title: Cancer Med. doi: 10.1002/cam4.2474 – volume: 26 start-page: 3329 issue: 23 year: 2007 ident: 10.1016/j.bcp.2023.115921_b0060 article-title: Negative regulation of chemokine receptor CXCR4 by tumor suppressor p53 in breast cancer cells: implications of p53 mutation or isoform expression on breast cancer cell invasion publication-title: Oncogene doi: 10.1038/sj.onc.1210120 – volume: 12 start-page: 2692 issue: 17 year: 2011 ident: 10.1016/j.bcp.2023.115921_b0215 article-title: Evaluation of a fluorescent derivative of AMD3100 and its interaction with the CXCR4 chemokine receptor publication-title: Chembiochem doi: 10.1002/cbic.201100441 – volume: 84 start-page: 1666 issue: 12 year: 2004 ident: 10.1016/j.bcp.2023.115921_b0075 article-title: CXCL12–CXCR4 interactions modulate prostate cancer cell migration, metalloproteinase expression and invasion publication-title: Lab. Invest. doi: 10.1038/labinvest.3700181 – volume: 71 start-page: 4744 issue: 6 year: 1997 ident: 10.1016/j.bcp.2023.115921_b0225 article-title: Role of the first and third extracellular domains of CXCR-4 in human immunodeficiency virus coreceptor activity publication-title: J. Virol. doi: 10.1128/jvi.71.6.4744-4751.1997 – volume: 4 start-page: 2171 issue: 12 year: 2013 ident: 10.1016/j.bcp.2023.115921_b0025 article-title: Chemokines in tumor progression and metastasis publication-title: Oncotarget doi: 10.18632/oncotarget.1426 – volume: 8 start-page: e74548 issue: 9 year: 2013 ident: 10.1016/j.bcp.2023.115921_b0115 article-title: Preclinical development of a novel class of CXCR4 antagonist impairing solid tumors growth and metastases publication-title: PLoS One doi: 10.1371/journal.pone.0074548 – volume: 38 start-page: 668 issue: 4 year: 1994 ident: 10.1016/j.bcp.2023.115921_b0195 article-title: Highly potent and selective inhibition of human immunodeficiency virus by the bicyclam derivative JM3100 publication-title: Antimicrob. Agents Chemother. doi: 10.1128/AAC.38.4.668 – volume: 72 start-page: 588 issue: 5 year: 2006 ident: 10.1016/j.bcp.2023.115921_b0210 article-title: Characterization of the molecular pharmacology of AMD3100: a specific antagonist of the G-protein coupled chemokine receptor, CXCR4 publication-title: Biochem. Pharmacol. doi: 10.1016/j.bcp.2006.05.010 – volume: 28 start-page: 443 issue: 5 year: 2004 ident: 10.1016/j.bcp.2023.115921_b0030 article-title: Chemokines publication-title: Dev. Comp. Immunol. doi: 10.1016/j.dci.2003.09.006 – volume: 6 year: 2015 ident: 10.1016/j.bcp.2023.115921_b0175 article-title: Diversity and inter-connections in the CXCR4 chemokine receptor/ligand family: molecular perspectives publication-title: Front. Immunol. doi: 10.3389/fimmu.2015.00429 – volume: 113 start-page: 4711 issue: 19 year: 2009 ident: 10.1016/j.bcp.2023.115921_b0045 article-title: CXCR4 is a key regulator of neutrophil release from the bone marrow under basal and stress granulopoiesis conditions publication-title: Blood doi: 10.1182/blood-2008-09-177287 – volume: 49 start-page: 525 issue: 1 year: 2010 ident: 10.1016/j.bcp.2023.115921_b0140 article-title: Fluorogenic “click” reaction for labeling and detection of DNA in proliferating cells publication-title: Biotechniques doi: 10.2144/000113463 – volume: 59 start-page: 8369 issue: 18 year: 2016 ident: 10.1016/j.bcp.2023.115921_b0120 article-title: Exploring the N-terminal region of CXC motif chemokine 12 (CXCL12): Identification of plasma-stable cyclic peptides as novel, potent CXC chemokine receptor type 4 (CXCR4) antagonists publication-title: J. Med. Chem. doi: 10.1021/acs.jmedchem.6b00695 – volume: 113 start-page: 5720 issue: 23 year: 2009 ident: 10.1016/j.bcp.2023.115921_b0100 article-title: Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma publication-title: Blood doi: 10.1182/blood-2008-08-174946 – volume: 25 start-page: 2216 year: 2008 ident: 10.1016/j.bcp.2023.115921_b0135 article-title: Click chemistry, a powerful tool for pharmaceutical sciences publication-title: Pharm. Res. doi: 10.1007/s11095-008-9616-1 – volume: 14 start-page: 1541 issue: 8 year: 2022 ident: 10.1016/j.bcp.2023.115921_b0105 article-title: Recent Advances in CXCL12/CXCR4 Antagonists and Nano-Based Drug Delivery Systems for Cancer Therapy publication-title: Pharmaceutics doi: 10.3390/pharmaceutics14081541 – volume: 73 start-page: 6598 issue: 8 year: 1999 ident: 10.1016/j.bcp.2023.115921_b0230 article-title: Mutagenesis of CXCR4 identifies important domains for human immunodeficiency virus type 1 X4 isolate envelope-mediated membrane fusion and virus entry and reveals cryptic coreceptor activity for R5 isolates publication-title: J. Virol. doi: 10.1128/JVI.73.8.6598-6609.1999 – volume: 8 start-page: 616 issue: 5 year: 2008 ident: 10.1016/j.bcp.2023.115921_b0250 article-title: Discovering and improving novel peptide therapeutics publication-title: Curr. Opin. Pharmacol. doi: 10.1016/j.coph.2008.06.002 – volume: 21 start-page: 1912 issue: 10 year: 2010 ident: 10.1016/j.bcp.2023.115921_b0130 article-title: Labeling live cells by copper-catalyzed alkyne− azide click chemistry publication-title: Bioconjug. Chem. doi: 10.1021/bc100272z – ident: 10.1016/j.bcp.2023.115921_b0005 doi: 10.3322/caac.21763 – volume: 276 start-page: 42826 issue: 46 year: 2001 ident: 10.1016/j.bcp.2023.115921_b0180 article-title: Structural and functional characterization of human CXCR4 as a chemokine receptor and HIV-1 co-receptor by mutagenesis and molecular modeling studies publication-title: J. Biol. Chem. doi: 10.1074/jbc.M106582200 – volume: 331 start-page: 1559 issue: 6024 year: 2011 ident: 10.1016/j.bcp.2023.115921_b0020 publication-title: A Perspective on Cancer Cell Metastasis, Science – ident: 10.1016/j.bcp.2023.115921_b0095 doi: 10.1042/bst0320366 – volume: 279 start-page: 3033 issue: 4 year: 2004 ident: 10.1016/j.bcp.2023.115921_b0205 article-title: Molecular mechanism of AMD3100 antagonism in the CXCR4 receptor: transfer of binding site to the CXCR3 receptor publication-title: J. Biol. Chem. doi: 10.1074/jbc.M309546200 – volume: 12 start-page: e0178943 issue: 6 year: 2017 ident: 10.1016/j.bcp.2023.115921_b0245 article-title: Differential stability of therapeutic peptides with different proteolytic cleavage sites in blood, plasma and serum publication-title: PLoS One doi: 10.1371/journal.pone.0178943 – volume: 16 start-page: 2927 issue: 11 year: 2010 ident: 10.1016/j.bcp.2023.115921_b0035 article-title: CXCL12 (SDF-1)/CXCR4 pathway in cancer publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-09-2329 – volume: 425 start-page: 307 issue: 6955 year: 2003 ident: 10.1016/j.bcp.2023.115921_b0080 article-title: Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL publication-title: Nature doi: 10.1038/nature01874 – volume: 40 start-page: 2004 issue: 11 year: 2001 ident: 10.1016/j.bcp.2023.115921_b0260 article-title: Click chemistry: diverse chemical function from a few good reactions publication-title: Angew. Chem. Int. Ed. doi: 10.1002/1521-3773(20010601)40:11<2004::AID-ANIE2004>3.0.CO;2-5 – volume: 9 start-page: e98231 issue: 5 year: 2014 ident: 10.1016/j.bcp.2023.115921_b0170 article-title: CXC chemokine CXCL12 and its receptor CXCR4 in tree shrews (Tupaia belangeri): structure, expression and function publication-title: PLoS One doi: 10.1371/journal.pone.0098231 – volume: 25 start-page: 413 issue: 8 year: 2004 ident: 10.1016/j.bcp.2023.115921_b0240 article-title: Historical review: a brief history and personal retrospective of seven-transmembrane receptors publication-title: Trends Pharmacol. Sci. doi: 10.1016/j.tips.2004.06.006 – volume: 13 start-page: eaay5024 issue: 640 year: 2020 ident: 10.1016/j.bcp.2023.115921_b0165 article-title: Functional anatomy of the full-length CXCR4-CXCL12 complex systematically dissected by quantitative model-guided mutagenesis publication-title: Sci. Signal. doi: 10.1126/scisignal.aay5024 – volume: 79 start-page: 1930 issue: 3 year: 2005 ident: 10.1016/j.bcp.2023.115921_b0185 article-title: Anti-CXCR4 monoclonal antibodies recognizing overlapping epitopes differ significantly in their ability to inhibit entry of human immunodeficiency virus type 1 publication-title: J. Virol. doi: 10.1128/JVI.79.3.1930-1933.2005 – volume: 60 start-page: 164 issue: 1 year: 2001 ident: 10.1016/j.bcp.2023.115921_b0200 article-title: Mutation of Asp171 and Asp262 of the chemokine receptor CXCR4 impairs its coreceptor function for human immunodeficiency virus-1 entry and abrogates the antagonistic activity of AMD3100 publication-title: Mol. Pharmacol. doi: 10.1124/mol.60.1.164 – volume: 49 start-page: 1385 issue: 3 year: 2021 ident: 10.1016/j.bcp.2023.115921_b0040 article-title: Latest update on chemokine receptors as therapeutic targets publication-title: Biochem. Soc. Trans. doi: 10.1042/BST20201114 – volume: 5 start-page: 657 issue: 6 year: 2004 ident: 10.1016/j.bcp.2023.115921_b0235 article-title: Postgenomic characterization of G-protein-coupled receptors publication-title: Pharmacogenomics doi: 10.1517/14622416.5.6.657 |
| SSID | ssj0006861 |
| Score | 2.466648 |
| Snippet | [Display omitted]
Cancer metastasis is the cause of up to 90 % of cancer related mortality. The CXCR4 receptor and its cognate ligand, CXCL12, have major roles... Cancer metastasis is the cause of up to 90 % of cancer related mortality. The CXCR4 receptor and its cognate ligand, CXCL12, have major roles in enabling... Cancer metastasis is the cause of up to 90 % of cancer related mortality. The CXCR4 receptor and its cognate ligand, CXCL12, have major roles in enabling... |
| SourceID | proquest pubmed crossref elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 115921 |
| SubjectTerms | Cell Line, Tumor Cell Movement Chemokine CXCL12 - metabolism Chemokine receptor CXCL12 CXCR4 CXCR4 antagonist Fluorescent Dyes Humans Maleimide Migration Neoplasm Metastasis - prevention & control Receptors, CXCR4 Signal Transduction |
| Title | The development of potent, competitive CXCR4 antagonists for the prevention of cancer metastasis |
| URI | https://dx.doi.org/10.1016/j.bcp.2023.115921 https://www.ncbi.nlm.nih.gov/pubmed/37956893 https://www.proquest.com/docview/2891753712 |
| Volume | 218 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9wwEB5CemgvpU1f2zRBhZJDWTe2Jc-uj8E0bFIaQklgb6qsR9nS2kvsHHLJb--MH1lySA492paw0Ayjb9A33wB8Yu1bkzkZJTK4iKKkiUqlXGSCpYRIoZ-VXCj8_QwXl-p0mS23oBhrYZhWOcT-PqZ30Xp4czjs5uF6teIa3xjTnPCD7ES8OQ4rNWMv_3K7oXngHIeueRjx6PFms-N4lZYlK1NJgSPL0-Shs-kh7NmdQccv4PkAHsVRv76XsOWrHXhajD3bduDgvFeivpmKi01hVTMVB-J8o1F98wp-0mfhNoQhUQexrgk_t1NhOyjdcYpEsSx-KEG7b37VrLHbCAK5gkCjWA_aT3XFcy07z5X461tDcLNZNa_h8vjrRbGIhmYLkZU5tpHEOFBqgTL2KTp0Ls69KufBGkpBAgaZO6tC7jGxMZP-jLOUCWU2zZPMzcnab2C7qiv_DkTwGJACcGxcokIoTekM8gVjcN54jxOIx23WdlAi54YYf_RIOfutyTKaLaN7y0zg892UdS_D8dhgNdpO3_MlTcfEY9M-jnbWZDa-ODGVr68bTUkpC5rOknQCb3sHuFuFnHHBZS7f_99Pd-EZP_UEmQ-w3V5d-z2COW253_nxPjw5Ovm2OPsHvoT8KA |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9tAEB6Cc0gvpU1f7nMLJYdiEUm7WlvHIBqcJjGhOODbdrWP4NJKJlIO-fedkVY2PSSHXrUatGiGb79hZ74B-ELatzqzPEq4txGipI5KIWykvcGESEg3LalR-HIh59fi-ypb7UEx9MJQWWXA_h7TO7QOT47D3zzerNfU4xvLNEf-wDsRb8ThfVKnykawf3J2Pl9sAVnOZBicJyMyGC43uzKv0pBqZcoRO7I8TR46nh6in90xdPoMngb-yE76LT6HPVcdwkExjG07hKOrXoz6fsKWu96qZsKO2NVOpvr-BfzEZWZ3NUOs9mxTI4VuJ8x0bLorK2LFqvghGDpA39Qks9sw5LkMeSPbBPmnuiJbQ_Fzy_64ViPjbNbNS7g-_bYs5lGYtxAZnss24jL2mF1IHrtUWmltnDtRzrzRmIV46XlujfC5k4mJqe5PW4PJUGbSPMnsDB3-CkZVXbk3wLyTXiIGx9omwvtSl1ZLumP01mnn5Bji4TcrE8TIaSbGbzVUnf1S6BlFnlG9Z8bwdWuy6ZU4HntZDL5T_4STwpPiMbPPg58Vuo3uTnTl6rtGYV5KmqbTJB3D6z4AtrvgU-q5zPnb__voJziYLy8v1MXZ4vwdPKGVvl7mPYza2zv3AVlPW34MUf0XYHH-2Q |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+development+of+potent%2C+competitive+CXCR4+antagonists+for+the+prevention+of+cancer+metastasis&rft.jtitle=Biochemical+pharmacology&rft.au=Hamshaw%2C+Isabel&rft.au=Cominetti%2C+Marco+M.D.&rft.au=Lai%2C+Wing-Yee&rft.au=Searcey%2C+Mark&rft.date=2023-12-01&rft.pub=Elsevier+Inc&rft.issn=0006-2952&rft.volume=218&rft_id=info:doi/10.1016%2Fj.bcp.2023.115921&rft.externalDocID=S0006295223005142 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0006-2952&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0006-2952&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0006-2952&client=summon |